Legal & General Group
MLTX icon

Legal & General Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Legal & General Group’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$383K Buy
20,559
+4,481
+28% +$74.2K ﹤0.01% 2433
2025
Q4 		$212K Sell
16,078
-4,827
-23% -$57K ﹤0.01% 2579
2025
Q3 		$150K Hold
20,905
– – ﹤0.01% 2604
2025
Q2 		$987K Buy
20,905
+1,425
+7% +$58K ﹤0.01% 2243
2025
Q1 		$761K Hold
19,480
– – ﹤0.01% 2271
2024
Q4 		$1.05M Buy
19,480
+1,429
+8% +$73K ﹤0.01% 2221
2024
Q3 		$910K Buy
18,051
+2,261
+14% +$106K ﹤0.01% 2267
2024
Q2 		$694K Buy
+15,790
New +$669K ﹤0.01% 2311

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Legal & General Group's MLTX Position: Q1 2026 in Review

Legal & General Group increased its MoonLake Immunotherapeutics (MLTX) stake by 28% in Q1 2026, buying an estimated $74.2K and bringing the position to 20,559 shares worth $383K. The position accounts for ﹤0.01% of the portfolio, ranked #2433.

Legal & General Group first reported a position in MLTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.05M in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Legal & General Group held 20,559 shares of MoonLake Immunotherapeutics worth $383K as of Q1 2026.
  • Legal & General Group bought 4,481 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $74.2K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2433 holding.
  • Legal & General Group first reported a position in MoonLake Immunotherapeutics in Q2 2024 and has held it in 8 quarters since.
  • Legal & General Group's MoonLake Immunotherapeutics position peaked at $1.05M in Q4 2024.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.